integrated discovery
Drug discovery starts with finding the right biological target and confirming that modulating it can deliver real therapeutic benefit. We have experience supporting drug discovery endeavours from inception through to pre-clinical model studies. We deploy integrated cellular, biochemical, and mechanism-based assays to confirm target relevance and disease linkage laying the groundwork for robust progression into hit discovery.
At o2h discovery, we tailor high-quality hit-finding strategies across diverse target classes, including challenging “me too” and “undruggable” targets. Leveraging biochemical, biophysical, and high-throughput cellular platforms, we deliver high-confidence hits with clear on-target engagement and actionable SAR to accelerate drug discovery.
At o2h discovery, we accelerate hit-to-lead development through rational design, SAR confirmation, synthesis, biological assays, and early ADMET studies. By integrating pharmacology, DMPK, and medicinal chemistry, we enable faster design-make-testanalyse cycles, empowering biotech partners to make informed Go/No-Go decisions and advance molecules addressing unmet medical needs.
Lead Optimisation is a critical phase in the drug discovery and development process. During this stage promising lead compounds typically identified during the hit-to-lead phase undergo extensive refinement and optimisation. Our multidisciplinary approach enhances lead compounds via structure-guided design, ADMET fine-tuning, pharmacokinetic profiling, and safety assessment transforming leads into preclinical candidates.